NDAORALCAPSULE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYNDAMAX (tafamidis) is an oral small-molecule transthyretin (TTR) stabilizer approved by the FDA in May 2019 for treating transthyretin amyloidosis (ATTR). It works by binding to and stabilizing the transthyretin protein, slowing disease progression in patients with this rare, inherited or wild-type amyloid disorder.
$1.3BPart D
Peak9.2 years to LOEPeak-stage product generating $1.3B in Part D spending with 52,375 claims in 2023, indicating a mature, well-established market position with stable commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions
Started May 2026
15 enrolled
Healthy Adults
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions
Started Mar 2026
24 enrolled
Healthy
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Started Feb 2026
50 enrolled
Transthyretin Amyloid Cardiomyopathy
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Started Jun 2025
15 enrolled
Transthyretin Amyloid Polyneuropathy
A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults
Started Dec 2024
22 enrolled
Healthy
Worked on VYNDAMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.